世卫组织的Covax项目将为众多发展中国家提供新冠疫苗。应该说这是展现对第三世界国家影响力最好的舞台。
很可惜,Covax的订购合同里目前没有中国疫苗。
另外世卫组织Covax项目订购的牛津和Novavax疫苗都会由印度血清研究所生产。
所以,最大赢家其实是印度,不是名气更大的辉瑞摩德纳,不管你是英国,美国,法国,除了最先进的MRNA疫苗不外传,剩下的都made in India然后出口全世界。
The new deals announced today include the signing of an advance purchase agreement with AstraZeneca for 170 million doses of the AstraZeneca/Oxford candidate, and a memorandum of understanding (MoU) with Johnson & Johnson for 500 million doses of the Janssen candidate, which is currently being investigated as a single dose vaccine.. These deals are in addition to existing agreements COVAX has with the Serum Institute of India (SII) for 200 million doses – with options for up to 900 million doses more – of either the AstraZeneca/Oxford or Novavax candidates, as well as a statement of intent for 200 million doses of the Sanofi/GSK vaccine candidate.